Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-11-24
pubmed:abstractText
Activation of both beta(1)- and beta(2)-adrenoceptors increases the contractility of human atrial myocardium through cyclic AMP-dependent pathways. Cyclic AMP is hydrolised by phosphodiesterases, but little is known about which isoenzymes catalyse inotropically relevant cyclic AMP accumulated upon stimulation of beta-adrenoceptor subtypes. We have compared the positive inotropic effects of (-)-noradrenaline and (-)-adrenaline, mediated through beta(1)- and beta(2)-adrenoceptors, respectively, in the absence and presence of the PDE3 inhibitor cilostamide (300 nM) or PDE4 inhibitor rolipram (1 muM) on human atrial trabeculae from non-failing hearts. Cilostamide, but not rolipram, potentiated the effects of both (-)-noradrenaline and (-)-adrenaline. Cilostamide increased the -logEC(50)M of (-)-adrenaline more than of (-)-noradrenaline (P < 0.05), regardless of whether or not the patients had been chronically treated with beta-blockers. The results are consistent with a greater PDE3-catalysed hydrolysis of inotropically relevant cyclic AMP produced through beta(2)-adrenoceptors than beta(1)-adrenoceptors in human atrium.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases, http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide..., http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide..., http://linkedlifedata.com/resource/pubmed/chemical/Epinephrine, http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine, http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Quinolones, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-1, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-2, http://linkedlifedata.com/resource/pubmed/chemical/Rolipram, http://linkedlifedata.com/resource/pubmed/chemical/cilostamide
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0028-1298
pubmed:author
pubmed:issnType
Print
pubmed:volume
374
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
249-53
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:17106669-3',5'-Cyclic-AMP Phosphodiesterases, pubmed-meshheading:17106669-Adrenergic beta-Antagonists, pubmed-meshheading:17106669-Aged, pubmed-meshheading:17106669-Cyclic AMP, pubmed-meshheading:17106669-Cyclic Nucleotide Phosphodiesterases, Type 3, pubmed-meshheading:17106669-Cyclic Nucleotide Phosphodiesterases, Type 4, pubmed-meshheading:17106669-Dose-Response Relationship, Drug, pubmed-meshheading:17106669-Epinephrine, pubmed-meshheading:17106669-Female, pubmed-meshheading:17106669-Heart Atria, pubmed-meshheading:17106669-Humans, pubmed-meshheading:17106669-Hydrolysis, pubmed-meshheading:17106669-Male, pubmed-meshheading:17106669-Middle Aged, pubmed-meshheading:17106669-Myocardial Contraction, pubmed-meshheading:17106669-Myocardium, pubmed-meshheading:17106669-Norepinephrine, pubmed-meshheading:17106669-Phosphodiesterase Inhibitors, pubmed-meshheading:17106669-Quinolones, pubmed-meshheading:17106669-Receptors, Adrenergic, beta-1, pubmed-meshheading:17106669-Receptors, Adrenergic, beta-2, pubmed-meshheading:17106669-Rolipram
pubmed:year
2006
pubmed:articleTitle
Cilostamide potentiates more the positive inotropic effects of (-)-adrenaline through beta(2)-adrenoceptors than the effects of (-)-noradrenaline through beta (1)-adrenoceptors in human atrial myocardium.
pubmed:affiliation
Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany, christ@rcs.urz.tu-dresden.de.
pubmed:publicationType
Journal Article, Comparative Study, In Vitro